

FOR IMMEDIATE RELEASE

RIBOPRO Secures Series A Funding to Accelerate mRNA-Based technologies

Oss, Netherlands – 31 October 2024 – RIBOPRO, a leading technology and service provider, specializing in the development and production of mRNA and lipid nanoparticles, today proudly announced the successful closing of a Series A funding round. The round saw participation from existing investors Vlasroot, Rockstart, BOM Brabant Ventures, some private investors and new investor Mountainview Capital Partners.

“We are thrilled to announce the successful closing of our Series A funding round. This milestone is a testament to the hard work and dedication of our team, and we are incredibly grateful for the support of our investors,” said Sander van Asbeck, CEO and co-founder of RIBOPRO. “This funding will propel our mission to transform the industry with pioneering mRNA and LNP technologies and offer a variety of solutions to address the current challenges in the field. One of them being a cutting-edge and agile mRNA/LNP manufacturing machine, enabling the healthcare industry to prepare for both future pandemics as well as providing the ability to produce personalized cancer therapies in an agile and cost-efficient way. “

Since its founding in 2020, RIBOPRO has rapidly become an essential player in the mRNA field. The company has developed several patented design- and process technologies, ensuring highly functional mRNA products for its worldwide client base. The new funding will enable RIBOPRO to scale its operations, invest in further development of its advanced technologies, and increase the marketing and sales efforts.

Mark van der Biezen, Partner at Mountainview Capital Partners (MVCP) and new investor for RIBOPRO highlights:

“The acquisition of a minority stake in RIBOPRO adds a biotech company to our portfolio, that has a leading position as an innovative and high-quality partner to their biotech and biopharma customers. We are excited to join a well-balanced group of seed investors who all bring the necessary experience to turn the company’s compelling growth prospects into reality, also leveraging our expertise from high tech precision manufacturing from our previous investments.”

Rune Theill, CEO of Rockstart, as an early-stage investor highlights:

“Rockstart is dedicated to empowering purpose-driven founders to scale their ventures and drive positive global change. This investment is a testament to the hard work of Sander and the RIBOPRO team, marking a significant milestone in their journey to revolutionize the future of healthcare. We are proud to have RIBOPRO in our portfolio and to continue alongside them in their journey.”

Paul Vernooij, Investment manager at BOM Brabant Ventures recognizes the value RIBOPRO brings to the industry:

“As an early investor in the company, BOM recognizes the significant value that companies like RIBOPRO bring to the development of novel mRNA technology and the local ecosystem. Through its current investment, BOM continues to support RIBOPRO and its ambition to introduce innovative mRNA solutions to the market.”

Roel Elshout, supervisory board member and representative of Vlasroot expressed his enthusiasm about this new milestone:

“Vlasroot is privileged to help RIBOPRO in its mission to become a leading player in the field of messenger RNA products globally. The current COVID-19 messenger RNA vaccines have shown the potential of the technology where messenger RNA has ripped up conventional timelines to start testing within weeks. We strongly believe that messenger RNA will change the industry forever and it is exciting to be part of that change. “

About RIBOPRO: RIBOPRO is a leading technology and service provider based in the Netherlands, specializing in mRNA and lipid nanoparticles (LNPs). RIBOPRO was started in 2020 from a desire to help innovators around the world bring new medicines to the patient. Both the manufacturing processes for high quality mRNA and LNPs, and several novel technologies were developed in-house to boost the performance of the mRNA and gain control over the delivery.

Customers use RIBOPRO's drug-product technologies such as sequence optimization algorithms and a novel LNP platform to lower the dose, enhance safety, boost immune responses, and/or deliver mRNA to organs other than the liver. In addition, RIBOPRO supports its customers with the manufacturing, quality control and optimization of mRNA and/or LNPs through CMO, CDMO and CRO services based on deep knowledge of mRNA.

About Mountainview Capital Partners: Mountainview Capital Partners is an independent Dutch investment firm founded in 2021 by former entrepreneurs. The current portfolio consists of significant minority stakes in 7 companies with a combined sales level of €750M and 1.200 employees.

About Rockstart: Rockstart is an early-stage investor that empowers purpose-driven founders across three domains: Energy, AgriFood, and Emerging Technologies. Rockstart invests in early-stage startups and provides access to capital, market, and expertise by connecting founders with co-investors, mentors, partners, corporates, and the wider Rockstart network. Rockstart has invested in more than 350 startups and its alumni value to date is more than \$1.7bn. Rockstart is an international team of +45 professionals dedicated to empowering purpose-driven founders to become scalable and drive positive change on a global scale. Rockstart has notable exits such as Wercker, Bouw7, iClinic, and in 2021, 3D Hubs, Brincr and Dan.com. The company has offices in Amsterdam, Netherlands, Copenhagen, Denmark, and Bogota, Colombia.

About BOM Brabant Ventures: BOM (the Brabant Development Agency) works together with entrepreneurs to create a strong, sustainable, and future-proof Brabant economy. BOM uses the Brabant Ventures label to focus, using knowledge and capital,

on the accelerated and future-proof growth of ambitious Brabant startups and scaleups in the high-tech systems and software, agri-food, life sciences & health, maintenance, supply chain, and bio-based economy top industries.

About Vlasroot: Vlasroot is a group of informal investors who focus on SME's with growth potential, a proven 'track record' and a strong management team. Companies that provide real solutions for real problems. We offer an experienced team with considerable experience in both business and investing and know how to make companies grow. We help companies to raise the bar and reach targets. We believe in co-creation and offer our network and expertise to our portfolio companies.

For media inquiries, please contact:

Silvy van Tuijl
Chief of Staff
RIBOPRO
info@RIBOPRO.eu
0031 85 060 67 62